1. Diversity in Phase 2 and Phase 3 Placebo‐Controlled, Double‐Blind, Lecanemab and Elenbecestat Early Alzheimer's Disease Studies. (20th December 2022) Authors: Grill, Joshua; Molina‐Henry, Doris P.; Sperling, Reisa A.; Dhadda, Shobha; Tranotti, Kate; Harris, Russell; Devins, Theresa; Swanson, Chad J; Kanekiyo, Michio; Gee, Michelle; Irizarry, Michael C; Kramer, Lynn D; Aisen, Paul; Raman, Rema Journal: Alzheimer's & dementia Issue: Volume 18(2022)Supplement 10 Page Start: n/a Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗